High-Expenditure Disease in the EU-28: Does Drug Spend Correspond to Clinical and Economic Burden in Oncology, Autoimmune Disease and Diabetes?

Wolfgang Greiner (), Keyur Patel, Christina-Jane Crossman-Barnes, Troels Vingtoft Rye-Andersen, Christian Hvid and Tom Vandebrouck
Additional contact information
Wolfgang Greiner: Bielefeld University
Keyur Patel: IQVIA Ltd, HEOR
Christina-Jane Crossman-Barnes: IQVIA Ltd, HEOR
Troels Vingtoft Rye-Andersen: Novo Nordisk Region Europe Pharmaceuticals A/S
Christian Hvid: Novo Nordisk Region Europe Pharmaceuticals A/S
Tom Vandebrouck: Novo Nordisk Region Europe Pharmaceuticals A/S

PharmacoEconomics - Open, 2021, vol. 5, issue 3, No 4, 385-396

Abstract: Abstract Background Drug costs are increasing in Europe, and there is a heightened need to reduce pressure on healthcare systems. In 2017, oncology, autoimmune disease, and diabetes featured as the three highest therapy areas for drug spend in the EU-28. However, the absolute 1-year drug spend growth for diabetes did not feature within the ten fastest growing therapy areas. Objective This study explores the association between drug spend and disease burden in oncology, autoimmune disease, and diabetes in the EU-28. Methods Oncology, autoimmune disease and diabetes therapeutic areas were investigated using four methodologies. Historical and forecasted drug spend was analysed using the IQVIA MIDAS® drug sales database. Clinical and economic burden was estimated from targeted literature reviews. Trend analyses compared changes in drug spend with clinical burden using the Global Burden of Disease tool as the epidemiological reference. Cost per quality-adjusted life-years (QALYs) from UK health technology assessments were compared to interpret the health economic value. Results Oncology had the highest historical drug spend and growth compared with autoimmune disease and diabetes. Total drug spend and growth in oncology is forecasted to exceed diabetes by twofold. Increasing oncology drug spend historically did not correspond with reductions in mortality and morbidity. Diabetes had the lowest drug spend and greatest QALY/€1000 spent benefit. Conclusion This study indicates that drug spend may not correlate to clinical burden across diseases. Future research could stimulate debate on whether more equitable drug funding may improve disease management.

Date: 2021
References: View complete reference list from CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
http://link.springer.com/10.1007/s41669-020-00253-4 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:pharmo:v:5:y:2021:i:3:d:10.1007_s41669-020-00253-4

Ordering information: This journal article can be ordered from
http://www.springer.com/adis/journal/41669

DOI: 10.1007/s41669-020-00253-4

Access Statistics for this article

PharmacoEconomics - Open is currently edited by Timothy Wrightson and Christopher Carswell

More articles in PharmacoEconomics - Open from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().